Header Logo

Connection

MIMI I-NAN HU to Aged

Back to Details
This is a "connection" page, showing publications MIMI I-NAN HU has written about Aged.
MIMI I-NAN HU
Connection Strength
0.215
Aged
  1. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019 02 01; 26(2):241-250.
    View in: PubMed
    Score: 0.028
  2. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014 Sep; 99(9):3144-52.
    View in: PubMed
    Score: 0.020
  3. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013 Sep 18; 105(18):1417-20.
    View in: PubMed
    Score: 0.019
  4. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
    View in: PubMed
    Score: 0.008
  5. Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. J Clin Ultrasound. 2020 May; 48(4):227-230.
    View in: PubMed
    Score: 0.008
  6. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
    View in: PubMed
    Score: 0.007
  7. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.007
  8. Vandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29.
    View in: PubMed
    Score: 0.007
  9. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.007
  10. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251.
    View in: PubMed
    Score: 0.007
  11. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.007
  12. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018 Jan; 40(1):79-85.
    View in: PubMed
    Score: 0.006
  13. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
    View in: PubMed
    Score: 0.006
  14. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
    View in: PubMed
    Score: 0.006
  15. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.006
  16. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76.
    View in: PubMed
    Score: 0.006
  17. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
    View in: PubMed
    Score: 0.006
  18. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90.
    View in: PubMed
    Score: 0.006
  19. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
    View in: PubMed
    Score: 0.006
  20. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
    View in: PubMed
    Score: 0.005
  21. Vitamin D deficiency in mycosis fungoides and S?zary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):518-24.
    View in: PubMed
    Score: 0.005
  22. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.005
  23. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.005
  24. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):e398-400.
    View in: PubMed
    Score: 0.005
  25. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg. 2012 Jun; 36(6):1320-6.
    View in: PubMed
    Score: 0.004
  26. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg. 2012 Apr; 147(4):338-44.
    View in: PubMed
    Score: 0.004
  27. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
    View in: PubMed
    Score: 0.004
  28. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008 Jun; 23(6):826-36.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.